{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Endometrial+Carcinoma&page=2", "query": { "condition": "Refractory Endometrial Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Endometrial+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T13:33:09.189Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01237067", "title": "Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Breast Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 77, "start_date": "2011-02-07", "completion_date": "2019-12-12", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01237067" }, { "nct_id": "NCT00082823", "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 2, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082823" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 9, "location_summary": "Denver, Colorado • New Haven, Connecticut • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" }, { "nct_id": "NCT05001282", "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Endometrial Cancer", "Ovary Cancer", "Ovary Neoplasm", "Ovary Disease", "Ovary Metastasis", "Ovarian Diseases", "Ovarian Cancer Stage", "Ovarian Epithelial Cancer", "Ovarian Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Neoplasm Epithelial", "Ovarian Cancer Recurrent", "Endometrial Diseases", "Endometrial Adenocarcinoma", "Endometrial Carcinosarcoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrioid Adenocarcinoma", "Endometrial Neoplasms", "Endometrial Cancer Recurrent", "Endometrioid Tumor", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "ELU001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elucida Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-09-13", "completion_date": "2024-06-07", "has_results": false, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001282" }, { "nct_id": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "HR+ Breast Cancer", "CCNE1 Amplification", "HER2-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Gastric Cancer", "Esophageal Adenocarcinoma", "Carcinosarcoma" ], "interventions": [ { "name": "BLU-222", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-04-07", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252416" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT03660826", "title": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 288, "start_date": "2018-09-27", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 761, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 482 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03660826" }, { "nct_id": "NCT00669422", "title": "ChemoFx® PRO - A Post-Market Data Collection Study", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer", "Uterine Neoplasms", "Endometrial Cancer", "Vaginal Cancer", "Vulvar Cancer", "Cervical Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Precision Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2756, "start_date": "2006-10", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669422" }, { "nct_id": "NCT05891197", "title": "A Biomarker Screening Protocol for Participants With Solid Tumors", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Non-Small Cell Carcinoma of Lung, TNM Stage 4", "Advanced Breast Cancer", "Advanced Lung Carcinoma", "NSCLC", "NSCLC, Recurrent", "NSCLC Stage IV", "Relapsed Cancer", "Relapse/Recurrence", "Recurrent Breast Cancer", "Recurrent NSCLC", "Platinum-resistant Ovarian Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Endometrioid Tumor", "High Grade Serous Carcinoma", "Ovarian Epithelial Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2023-05-19", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 1, "location_summary": "Rocky Mount, North Carolina", "locations": [ { "city": "Rocky Mount", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891197" }, { "nct_id": "NCT00003127", "title": "S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 57, "start_date": "1998-02", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-06-25T13:33:09.189Z", "location_count": 94, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003127" } ] }